A 4-month Treatment, Randomized, Double-blind, Placebo-Controlled, Multi-centre, Parallel-Group Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of Different Dosing Regimens of AZD1656 as Monotherapy in Japanese Type 2 Diabetes Mellitus Patients.
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2017
At a glance
- Drugs AZD 1656 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 11 Jul 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 11 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.